Robotic Biopsy Devices Market
Report ID: SQMIG35A3578
Report ID: SQMIG35A3578
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3578 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Robotic Biopsy Devices Market size was valued at USD 540.6 Million in 2024 and is poised to grow from USD 601.15 Million in 2025 to USD 1405.46 Million by 2033, growing at a CAGR of 11.2% during the forecast period (2026-2033).
The primary driver behind the robotic biopsy devices market is the convergence of clinical demand for higher diagnostic accuracy and technological advances in robotics and imaging. This market comprises automated and semi-automated systems that guide biopsy needles under CT, MRI and ultrasound to obtain tissue samples with greater precision, and it matters because accurate sampling affects staging, treatment selection and patient outcomes. Historically the field evolved from manual palpation and freehand imaging guidance to image-registered robotic arms and needle-steering platforms, leading to reduced complication rates and faster procedures, for example MRI-compatible robotic needle guides and CT-integrated robotic navigation systems worldwide.
Building on that evolution, the key trend driving the global robotic biopsy devices sector expansion is integration of advanced imaging, artificial intelligence and robotic control, because improved targeting reduces nondiagnostic samples and repeat procedures, which lowers cost and increases clinician adoption. As a result hospitals deploy robot-assisted lung and prostate biopsy platforms to reach small lesions that were previously inaccessible, enabling earlier cancer detection and enrollment in targeted therapy trials. Broader reimbursement for image-guided procedures and outpatient interventional radiology networks create further demand, and these dynamics open opportunities for modular, cloud-connected systems and service models that accelerate uptake across emerging and developed healthcare markets.
How Is AI Improving Diagnostic Accuracy in the Robotic Biopsy Devices Market?
Robots used in biopsy procedures include robots that utilize mechanical control of accurate placement of a needle into either small or deep lesions that cannot be accessed using manual methods. Artificial intelligence can assist the biopsy procedure by improving the interpretation of the images and by providing navigation and sampling guidance in real time. Some of the common applications of artificial intelligence in the context of biopsy include correcting image shifts caused by a change in the position of the patient and the body image during the biopsy procedure These functions reduce missed targets and improve sample quality while speeding workflow. As a result clinicians gain confidence in minimally invasive approaches and hospitals find robotic biopsy solutions more practical to adopt in routine care.
In October 2025, Intuitive Surgical announced FDA clearance of AI enabled software for its Ion endoluminal system that uses AI with shape sensing to adjust navigation during lung biopsy. This innovation improves targeting and workflow efficiency and supports market growth by increasing clinician confidence and accelerating adoption of robotic biopsy technology.
Market snapshot - (2026-2033)
Global Market Size
USD 540.6 Million
Largest Segment
Robotic Biopsy Guidance Systems
Fastest Growth
Software and Interfacing Modules
Growth Rate
11.2% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global robotic biopsy devices market is segmented by component, product modality, application area, end-user and region. Based on component, the market is segmented into Robotic Biopsy Guidance Systems, Biopsy Needles and Consumables and Software and Interfacing Modules. Based on product modality, the market is segmented into CT-Guided Robotic Biopsy Systems, MRI-Guided Robotic Biopsy Systems, Ultrasound/Cone-Beam CT Guided Systems and Others. Based on application area, the market is segmented into Lung Biopsy, Prostate Biopsy, Breast Biopsy, Neurosurgical/Brain Biopsy and Others. Based on end-user, the market is segmented into Hospitals and Integrated Health Networks, Specialized Cancer Diagnostic Centers and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What Role do Robotic Biopsy Guidance Systems Play in Advancing the Robotic Biopsy Devices Market?
Based on the global robotic biopsy devices market growth, robotic biopsy guidance systems segment dominates because they provide the core precision and workflow integration that enables automated targeting across tissue types. By combining real-time imaging registration, motion compensation, and stable instrument control, they reduce procedural variability and increase clinician confidence, which drives procurement decisions. Their importance for interoperating with needles and software provide a compelling value for attracting investor money for platform improvements and adoption of these platforms by major institutions.
However, biopsy needles and consumables are witnessing the strongest growth momentum as recurring disposable demand and procedure-specific innovations boost adoption. New needle designs optimized for robotic interfaces and tailored consumable kits simplify workflows, expand clinical indications, and create aftermarket revenue, accelerating future market expansion and opportunity creation among system manufacturers and suppliers.
How are MRI Guided Robotic Biopsy Systems Addressing Challenges in the Robotic Biopsy Devices Market?
CT-guided robotic biopsy systems segment dominates because CT-based imaging offers rapid, high-contrast visualization that aligns with established percutaneous biopsy workflows, enabling broad clinician acceptance. Because of their ability to integrate with already established patient intervention suites and predictable imaging geometries, thus simplifying robotic kinematics and registration, vendors can remove numerous integration barriers by applying significant engineering resources towards CT solutions. This consequently strengthens the evolution of the ecosystem as well as influencing referral patterns and purchasing decisions; this continues to support those companies leading modality focused robotic biopsy deployments.
However, MRI-guided robotic biopsy systems are witnessing the strongest growth momentum as superior soft-tissue contrast enables targeting of challenging lesions. Improvements in MRI-compatible robotics, clearer regulatory pathways for interventional MRI, and growing clinician interest in precision biopsies drive pilot adoption and investment, making MRI-guided systems a key source of future high-value procedural expansion.
To get detailed segments analysis, Request a Free Sample Report
Why does North America Dominate the Global Robotic Biopsy Devices Market?
As per the global robotic biopsy devices regional market share, North America maintains a commanding position due to integrated strengths across clinical infrastructure, research ecosystems, and payer frameworks that support technology adoption. Robotic biopsy technologies are being adopted by academic and treating hospitals who evaluate and incorporate devices into their workflows. This iterative refinement of technology through feedback gathered from actual clinical experiences will enable better use of robotic biopsy tools. The collaborative efforts of manufacturers, key clinical opinion leaders, and regulatory bodies allow for improved access to the marketplace and improved physician education programs. Additionally, there is an established environment for commercializing technologies through large investments into the healthcare sector; which translates into higher procedure volumes through established networks of specialists and referral pathways, thus accelerating the adoption of robotic biopsy devices.
United States Robotic Biopsy Devices Market
Robotic biopsy devices market in United States is driven by concentrated centers of excellence, extensive clinical trial activity, and collaboration with leading academic hospitals. A high volume of procedures being conducted in specialized facilities enables the clinician to become more proficient at performing these procedures and also allows for ongoing evaluation and improvement of the devices used in performing these procedures. A supportive investment environment and established reimbursement models promote the commercial use and training on robotic biopsy technologies.
Canada Robotic Biopsy Devices Market
Robotic biopsy devices market in Canada is growing network of tertiary centers and collaborative research hospitals supports adoption of robotic biopsy platforms. Provincial decision-makers evaluate the clinical value of robotic biopsies, while pilot programs facilitate the establishment of protocol and curriculum for training. Public institutions work closely with vendors to better adapt to system-level requirements and will continue to emphasize patient safety and minimally invasive procedures.
What is Driving the Rapid Expansion of Robotic Biopsy Devices Market in Europe?
Based on global robotic biopsy devices regional forecast, Europe is experiencing rapid expansion driven by harmonized regulatory frameworks, strong clinical networks, and focused investment in minimally invasive diagnostics. Global professional associations and training ensembles across international borders foster establishing collaborative assessments of robotic biopsy technology throughout different clinical specialties, thus creating verifiable real-world data to facilitate broader implementation. International societies and training programs also promote consistent standards of practice and clinician competency in performing procedures. Public and private payers are also beginning to acknowledge the value of precision diagnostics over time. Through partnerships with multinational companies, as well as indigenous manufacturing capabilities, these devices are soon becoming available globally in greater numbers and customized to meet very specific needs within local clinics.
Germany Robotic Biopsy Devices Market
Robotic biopsy devices market in Germany is strong medical technology sector, close collaboration between industry and academic hospitals, and emphasis on precision diagnostics underpin leadership in robotic biopsy adoption. Clinical opinion leaders do comparative evaluations, and distributed training programs help spread the word. While national procurement frameworks and established referral networks send complex diagnostic tests to centers with state-of-the-art equipment, they also allow performance evaluation and iterative product adjustments to meet both quality and safety standards.
United Kingdom Robotic Biopsy Devices Market
Robotic biopsy devices market in United Kingdom Accelerated adoption reflects strong clinician engagement, targeted public funding for diagnostics, and an active medtech innovation community. Rapid dissemination of techniques is made possible through clinical training programs and pilot initiatives. Integrated health systems support timely assessment of solutions, as well as scaling the most successful ones. With a focus on minimally invasive methods of treatment and high-quality experiences for patients throughout their care process and combined with cooperative relationships among hospitals/clinics.
France Robotic Biopsy Devices Market
Robotic biopsy devices market in France is supported by national initiatives in precision medicine, expanding clinical evaluation programs and investments by healthcare providers. Academic hospitals and specialty clinics pilot robotic biopsy applications to adapt workflows and training to local care models. Patient-centered needs are driving the development and introduction of diagnostics and less invasive methods to facilitate progressive assimilation. Vendor relationships promote the localization of solutions and help ensure that devices meet both regulatory and clinical standards.
How is Asia Pacific Strengthening its Position in Robotic Biopsy Devices Market?
As per global robotic biopsy devices regional outlook, Asia Pacific is strengthening its role through a combination of localized innovation, investment in advanced imaging infrastructure, and expanding clinical expertise in minimally invasive procedures. Robotic biopsy systems are being assessed by regional centers of excellence and specialty private hospitals for use with their regional patients and procedures; as a result, many institutions are collaborating domestically with manufacturers and internationally with technology vendors on developing customized robotic solutions. In addition, many institutions are partnering with others to offer training and knowledge transfer to improve their clinician capacity, while healthcare systems are focused on improving the efficiency of the diagnostic process and the experience of patients. Cost-sensitive purchasing practices and public-private partnerships are facilitating the scalable use of robotic biopsy systems in a wide variety of settings, and their use in telemedicine is providing new opportunities for expanding access for geographically dispersed populations.
Japan Robotic Biopsy Devices Market
Robotic biopsy devices market in Japan is mature medical device industry and strong clinical research base support evaluation and integration of robotic biopsy technologies. Hospitals that are leading the way use both the expertise of imaging and navigation to create refined standard operating procedures. At the same time, local manufacturers work with international partners to create tailored systems that fit into local clinical workflows. Precision diagnostics and patient safety will be key to how these should be implemented, which relies on clinician training and pilot program results in order to grow more widely.
South Korea Robotic Biopsy Devices Market
Robotic biopsy devices market in South Korea is dynamic medtech ecosystem, skilled interventional radiology community, and focus on technology driven healthcare support adoption. Hospitals that offer advanced imaging services are being used as pilot sites to try out robotic biopsy procedures. The clinical evaluation of robotic biopsy systems, training clinicians to perform robotic biopsy procedures and alignment of robotic biopsy systems with the national health priorities for Canada will help successfully integrate robotic biopsy technologies into care pathways across regional networks.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Adoption Of Minimally Invasive Procedures
Enhanced Imaging and Automation Capabilities
Restraints
High Upfront Costs and Maintenance
Regulatory Hurdles and Reimbursement Challenges
Request Free Customization of this report to help us to meet your business objectives.
Competition in the global robotic biopsy devices market outlook is shaped by consolidation, platform differentiation and imaging integration, with expanded lung cancer screening increasing demand for bronchoscopic biopsy tools. Strategic moves include Johnson and Johnson’s Auris Health acquisition and Intuitive Surgical’s Ion approval, while targeted partnerships and imaging integrations such as Mendaera’s deal with Butterfly accelerate commercialization and raise competitive intensity.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global robotic biopsy devices industry is driven primarily by the integration of advanced imaging and AI-driven robotic control that improves targeting and diagnostic accuracy, and further supported by growing adoption of minimally invasive procedures that prioritize patient safety and workflow efficiency. However high upfront costs and ongoing maintenance remain a significant restraint limiting penetration in smaller hospitals. North America is the dominating region and Robotic Biopsy Guidance Systems the dominating segment due to strong clinical infrastructure, research collaboration and reimbursement pathways. Organizations that develop interoperable platforms and provide software upgrades will be the most successful as hospitals, specialty care and outpatient facilities continue to grow.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 540.6 Million |
| Market size value in 2033 | USD 1405.46 Million |
| Growth Rate | 11.2% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Robotic Biopsy Devices Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Robotic Biopsy Devices Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Robotic Biopsy Devices Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Robotic Biopsy Devices Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Robotic Biopsy Devices Market size was valued at USD 540.6 Million in 2024 and is poised to grow from USD 601.15 Million in 2025 to USD 1405.46 Million by 2033, growing at a CAGR of 11.2% during the forecast period (2026-2033).
Competition in the global robotic biopsy devices market is shaped by consolidation, platform differentiation and imaging integration, with expanded lung cancer screening increasing demand for bronchoscopic biopsy tools. Strategic moves include Johnson and Johnson’s Auris Health acquisition and Intuitive Surgical’s Ion approval, while targeted partnerships and imaging integrations such as Mendaera’s deal with Butterfly accelerate commercialization and raise competitive intensity. 'Intuitive Surgical', 'Medtronic', 'Johnson & Johnson', 'Stryker', 'Siemens Energy', 'Biojet', 'Renishaw', 'iSYS Medizintechnik', 'Interventional Systems', 'XACT Robotics', 'Perfint Healthcare', 'Apollo Endosurgery', 'Stereotaxis', 'Hansen Medical', 'Mazor Robotics', 'Medtech SA', 'Transenterix', 'Titan Medical', 'PROCEPT BioRobotics', 'Endomaster'
Robotic biopsy systems enable more precise targeting of lesions and reduce collateral tissue trauma, which supports clinician confidence and broader clinical adoption over time. This precision enhances sample quality and procedural consistency, leading healthcare providers to prioritize platforms that improve diagnostic workflows. Hospitals and specialty centers seek technologies that align with patient safety and outcome objectives, prompting procurement and integration of robotic biopsy solutions across care pathways. As clinical preference shifts toward interventions that minimize complications and improve diagnostic confidence, market demand for these devices strengthens.
Integration With Imaging Platforms: Convergence of robotic biopsy platforms with multimodality imaging is improving procedural accuracy and clinical workflow. Real time image guidance supports precise targeting of lesions, reduces repeat sampling, and facilitates minimally invasive approaches. Tight integration with radiology systems and hospital IT enables streamlined scheduling, reporting, and cross disciplinary collaboration. Vendors are pursuing interoperable interfaces and partnerships to embed robotics within diagnostic pathways, increasing perceived value among clinicians and health systems while supporting adoption through improvements in reliability, consistency, and patient experience.
Why does North America Dominate the Global Robotic Biopsy Devices Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
